LENZ Therapeutics Inc (LENZ)
Featured in
High-Beta Stocks
LENZ Therapeutics, Inc. is a NASDAQ-listed common stock company in the healthcare sector focused on pharmaceutical development and commercialization. The business centers on therapies aimed at improving vision in the United States, with product candidates including VIZZ and LNZ101 for presbyopia in adults. The company was established in 2013 and is headquartered in Solana Beach, California. It was previously known as Presbyopia Therapies, Inc. before adopting the LENZ Therapeutics, Inc. name in June 2021.
Stock Summary
Fair Value
Profitability & Growth
Quality & Risk
Events & Dividends
Technical Outlook
FAQ
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-LENZ
|
$8.15
|
63.7% Upside
|
Bargain
|
$32
|
542.6% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 19, 2026
|
-1.4x
|
0.6x
|
7.4x
|
155.5 M
|
-101.6 M
|
0.4%
|
53.8%
|
12.9
|
—
|
80.2%
|
